Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | VNN1 | O95497 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4058790 | 0.79 | SLC6A2 (0.34) | SLC6A2SLC6A4VNN1ROCK2EPHX2 | |
| SCHEMBL4058962 | 0.79 | EPHX1 (0.39) | — | |
| SCHEMBL4063927 | 0.73 | SLC6A2 (0.36) | SLC6A2SLC6A4VNN1EPHX2CYP3A4 | |
| SCHEMBL4061953 | 0.66 | CCR1 (0.32) | — | |
| SCHEMBL4066245 | 0.66 | VNN1 (0.40) | SLC6A2SLC6A4VNN1EPHX2GRIN1 | |
| SCHEMBL4059569 | 0.65 | EPHX1 (0.40) | SLC6A4EPHX2SCN9A | |
| SCHEMBL4062024 | 0.64 | EPHX1 (0.44) | VNN1SCN9A | |
| SCHEMBL4060519 | 0.64 | CCR1 (0.37) | SLC6A2CYP2C19SCN9A | |
| SCHEMBL4071304 | 0.64 | CCR1 (0.40) | SLC6A2SLC6A4VNN1EPHX2BRD4 | |
| SCHEMBL4248290 | 0.63 | CCR1 (0.35) | SLC6A2SLC6A4SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0966443-B1 | HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR | PFIZER (US) | 2009-01-28 | — | — | EP | disclosed |
| US-20020198207-A1 | Novel Hexanoic acid derivatives | KATH JOHN CHARLES (US) | 2002-12-26 | — | — | US | disclosed |
| US-6403587-B1 | AUTOIMMUNE DISEASES, ACUTE AND CHRONIC INFLAMMATORY CONDITIONS, ALLERGIC CONDITIONS, INFECTION ASSOCIATED WITH INFLAMMATION, VIRAL, TRANSPLANTATION TISSUE REJECTION, ATHEROSCLEROSIS, RESTENOSIS, HIV INFECTIVITY, AND | PFIZER INC. | 2002-06-11 | — | — | US | disclosed |
| EP-0966443-A1 | HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR | PFIZER INC. (US) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998038167-A1 | HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR | PFIZER INC. (US) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198207-A1 | Novel Hexanoic acid derivatives | HCAR3, HCAR1, FFAR1 | SLC6A2 4660/4885SLC6A4 3845/4885VNN1 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.